Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
KN
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
KNSA
Mkt Cap
$6.13B
Volume
446.10K
Next Earnings
October 27th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
KN
KNSA
KN
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
KNSA
News
·
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Mkt Cap
$6.24B
Volume
446.10K
Next Earnings
October 27th
Chart
Financials
Earnings
News
About
Insider
Filings
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals reported Q2 2026 net product revenue of $243.6 million for ARCALYST, representing 55% year-over-year growth, and raised full-year 2026 guidance to $980-995 million. The company announced positive Phase 2 data for KPL-387 showing rapid pain and inflammation reduction, with the pivotal Phase 3 PASTORALE trial now enrolling patients. KPL-1161 development is on track for Phase 1 initiation by end of 2026. The company maintains a strong balance sheet with $525.9 million in cash and no debt.
GlobeNewswire Inc. · Jul 28, 2026
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today
Kinikska Pharmaceuticals International (KNSA) surged nearly 24% after reporting strong Q1 2026 earnings that beat analyst expectations. Revenue from its drug Arcalyst reached $214 million (vs. $138 million year-ago), and net income more than doubled to $22.6 million. The company raised its full-year Arcalyst sales guidance to $930-945 million, driven by recent approval for heart disorder pericarditis.
The Motley Fool · Apr 28, 2026
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
Kiniksa Pharmaceuticals received FDA Orphan Drug Designation for KPL-387, a monoclonal antibody targeting pericarditis treatment, with potential for monthly subcutaneous self-injection.
GlobeNewswire Inc. · Oct 17, 2025
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
Kiniksa Pharmaceuticals announces plans for a Phase 2/3 clinical trial of its drug KPL-387 in recurrent pericarditis, with the trial expected to initiate in mid-2025 and Phase 2 data expected in the second half of 2026.
GlobeNewswire Inc. · Jun 5, 2025
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa Pharmaceuticals announced that country star Carly Pearce has joined their Life DisRPted campaign to raise awareness for recurrent pericarditis. The company also reported strong Q1 2025 financial results for their ARCALYST product, with net product revenue of $137.8 million and increased 2025 revenue guidance.
GlobeNewswire Inc. · May 29, 2025
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
The article highlights three healthcare stocks that are considered good investments right now: AbbVie, Vertex Pharmaceuticals, and Kiniksa Pharmaceuticals. It discusses the growth prospects and financial metrics of these companies.
The Motley Fool · Mar 14, 2025
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Kiniksa Pharmaceuticals, a biopharmaceutical company, announced that it will host a conference call on February 25, 2025, to report its fourth quarter and full year 2024 financial results and recent portfolio execution.
GlobeNewswire Inc. · Feb 20, 2025
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight
The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions.
GlobeNewswire Inc. · Jan 14, 2025
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
The urticaria pipeline is rapidly expanding, with over 20 leading companies developing 25+ new treatments to address the rising prevalence of the condition. Advances in biologic therapies and a strong R&D pipeline are driving progress, while improved healthcare infrastructure and digital innovations enhance patient access and outcomes.
GlobeNewswire Inc. · Nov 4, 2024
Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –
GlobeNewswire Inc. · Jun 17, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
KN
KNSA
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Buy
Sell
Market
Limit
Soon
KNSA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any KNSA yet.
Related Tickers
Earnings